Last updated: July 26, 2026
Buspirone hydrochloride is an established oral anxiolytic (5-HT1A receptor partial agonist) with no meaningful near-term “brand-style” clinical-trials pipeline event that shifts market structure. Commercial dynamics are driven by patent/market history in the US and ex-US generics, plus ongoing incremental formulation and dosing-stability work typical for off-patent small molecules. A current, decision-grade view requires Orange Book status, trial registry activity, and confirmed launches by labeled indications, but those are not provided here.
What is the current clinical trials update for buspirone hydrochloride (2024–2026)?
No specific, verified buspirone hydrochloride clinical trial results or enrollment milestones are included in the available input. A complete update would require listing trial identifiers (NCT numbers), phase, enrollment status, locations, study endpoints (e.g., HAM-A, GAD-7, HAMA, CGI), and whether studies target GAD, treatment-resistant anxiety subpopulations, geriatric dosing, renal/hepatic impairment exposure, or alternative delivery (extended release). Without those data, a precise trial-by-trial update cannot be produced.
Which indications dominate buspirone clinical research?
A complete evidence map would normally segment studies into:
- Generalized anxiety disorder (GAD) symptom reduction
- Panic disorder adjunctive studies
- Sleep/anxiety comorbidity endpoints
- Population pharmacokinetics (PK) for hepatic/renal impairment
- Drug-drug interaction studies (CYP metabolism, SSRIs/SNRIs co-use)
What endpoints are used in buspirone trials?
Common anxiety trials endpoints typically include:
- HAM-A total score change
- Response defined by percent reduction in HAM-A
- CGI-S and CGI-I
- Functional outcomes and relapse rates
No trial-specific endpoint mapping is possible without registries or study reports.
What is the buspirone hydrochloride market size and current sales trend?
No market sizing, prescription counts, or revenue figures are included in the available input. A decision-grade market analysis would typically cover:
- US prescriptions (TRx) trend
- Wholesale acquisition cost and net price trend by manufacturer
- Share by label strength (e.g., 5 mg, 7.5 mg, 10 mg, 15 mg) and dosing frequency
- Payer mix and formulary placement
- Ex-US market fragmentation (EU, UK, Canada, Japan)
- Price erosion curves by generic entry wave
Without those inputs, market numbers and trend direction cannot be stated in a defensible way.
How concentrated is buspirone prescribing among manufacturers?
A proper answer would enumerate:
- Labeled ANDA entrants and authorized generics
- Launch years and subsequent share transfers
- State-level prescribing variability
- Switch rates from brand or earlier generics to newer generics
No such manufacturer-level data is provided.
When does buspirone hydrochloride lose exclusivity and can generics enter safely in the US?
A correct exclusivity/generic-landing answer needs US patent and Orange Book details:
- Listed Orange Book patents for the relevant NDA(s) or ANDA(s)
- Patent expiration dates
- Any pediatric exclusivity extensions (if applicable)
- Orange Book “Orange” status, delisting history
- Settlement agreements affecting Paragraph IV timing
The provided input does not include the Orange Book patent list, any expiration schedule, or litigation facts.
Is there any Orange Book exclusivity still relevant for buspirone?
No Orange Book status is provided in the input. A safe, accurate exclusivity statement cannot be produced.
What patents protect buspirone hydrochloride in major jurisdictions (US, EU, UK, Canada)?
A jurisdiction-by-jurisdiction patent estate requires:
- Patent family identification (primary composition, salts, processes, polymorphs, and specific dosing regimens)
- Publication and grant status
- Assignees
- Expiration by jurisdiction
No patent numbers, assignees, or claim scope details are included in the input.
How strong is the buspirone hydrochloride patent estate?
Without the patent list and claim coverage, strength scoring (litigation risk, remaining enforceability, ease of design-around) cannot be calculated.
Which companies manufacture and sell buspirone hydrochloride generics, and how does the competitive landscape look?
A competitive landscape requires:
- ANDA authorizations and launch dates
- Current NDC inventory
- Supply constraints and FDA inspection outcomes affecting availability
- Segmenting by immediate-release versus alternative release technologies
No manufacturer or NDC data is provided.
How does buspirone compare with competing anxiolytics on time-to-generic and prescribing?
A proper competitive comparison would cover:
- Benzodiazepines: controlled substance dynamics, abuse deterrence, prescriber risk
- Hydroxyzine and pregabalin: different evidence and payer behavior
- SSRIs/SNRIs: long-term anxiety management, different safety and titration profiles
No buspirone-specific competitive datasets are included.
What formulation patents exist for buspirone hydrochloride (IR, ER, salt form, polymorph, stability)?
A formulation patent answer requires a patent-by-patent review of:
- salt forms and specific manufacturing processes
- tablet/capsule compositions and excipient systems
- stability and shelf-life improvements
- polymorph or particle size distributions
- bioequivalence/PK bridging strategies for reformulations
No formulation patent details are supplied.
What patent litigation and settlements affect buspirone hydrochloride generic entry?
A litigation and settlement analysis needs:
- Case captions and court (e.g., District of Delaware, N.D. California)
- Paragraph IV notices and asserted patents
- Complaint and counterclaims timeline
- Stipulated dismissal or settlement terms (30-month stay, terminal disclaimers, carve-outs)
- Injunction outcomes or final judgments
No litigation data is provided.
What is the FDA regulatory status of buspirone hydrochloride (NDA/ANDA, labeling, bioequivalence requirements)?
A regulatory status section requires:
- NDA number(s) and reference listed drug (RLD)
- ANDA approval history
- Dosage forms and strengths in labeling
- Therapeutic equivalence evaluations and substitutability
- Any REMS and postmarketing requirements
No FDA regulatory artifacts are included in the input.
Are there any recent FDA actions (warning letters, recalls, shortages) for buspirone?
No FDA enforcement or shortage data is included in the input.
How do clinical-trial signals translate into commercialization for buspirone hydrochloride?
A commercialization bridge normally uses:
- Probability of technical success: endpoint superiority, non-inferiority margins
- Regulatory pathway: new indication vs label expansion vs formulation-only
- Pricing power assessment: whether trial outcomes justify differentiated product
- Payer acceptance likelihood based on evidence thresholds
- Interchangeability and competition impacts
No trial signals are supplied, so this linkage cannot be quantified.
Key Takeaways
- No data is provided in the input to support a trial-by-trial buspirone hydrochloride clinical update, patent-expiration timeline, Orange Book status, litigation history, or market sizing.
- A decision-grade business assessment for buspirone requires Orange Book patent lists, FDA/NDC current competitive landscape, and trial registry milestones; none are included here.
- Under typical conditions for established small-molecule anxiolytics, market outcomes are dominated by generic competition and minor formulation differentiation, but a specific projection cannot be stated without current registry and regulatory records.
FAQs
- What are the most common dosing strengths of buspirone hydrochloride and how do dosing patterns affect generic interchangeability?
- Are there any active NCT trials studying buspirone hydrochloride for anxiety subtypes beyond GAD?
- How does buspirone’s pharmacokinetic profile influence formulation bioequivalence study design?
- What are typical Paragraph IV litigation triggers for off-patent small-molecule anxiolytics like buspirone?
- How do payer formularies typically position buspirone versus first-line GAD therapies (SSRIs/SNRIs) in the generic era?
References
No sources were provided or cited.
